Open Orphan PLC Upcoming Investor Events

TIDMORPH

Open Orphan PLC

06 February 2020

RNS REACH

Open Orphan plc

("Open Orphan" or the "Company")

Upcoming Investor Events

Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 11(th) February to 26(th) March 2020.

Cathal Friel, Open Orphan's Executive Chairman, or Trevor Phillips, CEO, will be in attendance for all the events and will be presenting an update to existing and potential investors on the Company's acquisition of hVIVO and business plans for 2020. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. It also has Europe's only commercial 24 bed quarantine clinic and on-site virology laboratory at Queen Mary's Hospital in London.

A link to our investor presentation is available on our website at https://www.openorphan.com/sites/openorphan/files/Open%20Orphan%20Investor%20Deck_0.pdf

No new material information will be disclosed at any event.

A full schedule of the upcoming events is as follows:

 
         Event              Date/Time                     Location 
 Shares Magazine/Cenkos   February 11,     London - Business Design Centre, 
  Growth and Innovation    2020             London N1 52 Upper Street, Islington 
  Forum 
                           08:45 - 17:30 
 ShareSoc Growth          February 25,     Manchester - DoubleTree by Hilton 
  Company Seminar          2020             Hotel, One Piccadilly Place, 1 Auburn 
                                            Street, Manchester M1 3DG 
                           18:00 - 20:40 
                         ---------------  --------------------------------------- 
 Shares Magazine          February 25,     London - Novotel, Pepys Street, London 
  Investor Event           2020 
                           17:30 - 21:30 
                         ---------------  --------------------------------------- 
 ShareSoc Growth          March 11, 2020   London - Company Matters/Link Asset 
  Company Seminar                           Services, 65 GRESHAM STREET, London 
                                            EC2V 7NQ 
                           17:30 - 21:30 
                         ---------------  --------------------------------------- 
 ShareSoc Growth          March 17, 2020   Birmingham - Clayton Hotel Birmingham, 
  Company Seminar                           Albert Street, Birmingham B5 5JE 
                           18:00 - 20:40 
                         ---------------  --------------------------------------- 
 Proactive Investors      March 26, 2020   London - Chesterfield Mayfair Hotel, 
  One2One Forum                             35 Charles Street, London, W1J 5EB 
                           18:00 - 21:30 
                         ---------------  ---------------------------------------

Enquiries:

Open Orphan plc

Cathal Friel, Executive Chairman +353 (0)1 644 0007

Trevor Phillips, Chief Executive Officer +44 (0)20 7347 5350

Arden Partners plc (Nominated Adviser and Joint Broker) +44 (0)20 7614 5900

John Llewellyn-Lloyd / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) +353 (0)1 679 6363

Anthony Farrell

Camarco (Financial PR) +44 (0)20 3757 4980

Tom Huddart / Daniel Sherwen

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, phase I & II clinical trials design and execution. hVIVO, as an industry leading services provider in viral challenge studies and vaccine and viral laboratory services, supports product development for customers developing antivirals, vaccines and respiratory therapeutics , all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widening the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAEAXASEDDEEFA

(END) Dow Jones Newswires

February 06, 2020 02:01 ET (07:01 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024